BioCentury | Jan 13, 2021
Finance
IPO filing reveals details of Sana’s deep pipeline, aggregation of next-generation gene and cell therapy technologies
...cardiomyocytes to treat heart failure.Sana acquired glial progenitor cell engineering technology via its purchase of University of Rochester...